Fragment-based drug discovery campaigns guided by native mass spectrometry

Louise M. Sternicki and Sally-Ann Poulsen

RSC Med. Chem., 2024, 15, 2270
DOI: 10.1039/D4MD00273C

Toward routine utilisation of native mass spectrometry as an enabler of contemporary drug development

Louise M. Sternicki and Sally-Ann Poulsen

RSC Med. Chem., 2025, 16, 5114
DOI: 10.1039/D5MD00617A

Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors

Edward A. FitzGerald, Darius Vagrys, Giulia Opassi, Hanna F. Klein, David J. Hamilton, Vladimir O. Talibov, Mia Abramsson, Anna Moberg, Maria T. Lindgren, Claes Holmgren, Ben Davis, Peter O'Brien, Maikel Wijtmans, Roderick E. Hubbard, Iwan J.P. de Esch and U.Helena Danielson

SLAS Discovery, 2024, 29, 40
DOI: 10.1016/j.slasd.2023.09.001

Virtual screening and fragment growth strategy for developing near-infrared fluorescent probes to detect Aβ in Alzheimer's disease model

Guanyu Xu, Can Zhou, Geng Su, Zeying Liang, Jianyu Wu, Tiantian Tang, Yuemin Bian, Jian Cai, Yi Zou and Jian Yang

European Journal of Medicinal Chemistry, 2025, 292, 117695
DOI: 10.1016/j.ejmech.2025.117695

Iodoetherification as a strategy towards sp3-rich scaffolds for drug discovery

Lydia Barnes, Timothy N. Birkinshaw, Aaron J. Senior, Oscar Siles Brügge, William Lewis, Stephen P. Argent, Christopher J. Moody and Andrew Nortcliffe

Bioorganic & Medicinal Chemistry, 2024, 101, 117636
DOI: 10.1016/j.bmc.2024.117636

Linkers in fragment-based drug design: an overview of the literature

Dylan Grenier, Solène Audebert, Jordane Preto, Jean-François Guichou and Isabelle Krimm

Expert Opinion on Drug Discovery, 2023, 18, 987
DOI: 10.1080/17460441.2023.2234285